Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

GLP-1 Without Insurance 2026: 4 Cash-Pay Paths ($99-$449/mo)

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~11 min read

Without insurance in May 2026, the four legitimate cash paths for GLP-1 are: LillyDirect Zepbound single-dose vials ($299-$449/mo by dose), NovoCare Wegovy self-pay ($149-$349/mo depending on dose and intro window), 503A compounded semaglutide or tirzepatide through telehealth providers like Mochi, Henry Meds, or Remedy Meds ($99-$397/mo), and HSA/FSA payment for 22-37% effective tax savings layered on top of any of the above. Compounded is cheapest but not FDA-approved.

The 4 Cash Paths at a Glance

The GLP-1 cash-pay landscape changed materially between November 2025 and February 2026. Eli Lilly cut LillyDirect Zepbound vial prices on Feb 23 2026, bringing the 2.5mg starter dose down to $299/mo. Novo Nordisk launched an aggressive intro program at NovoCare in November 2025 ($149/mo for select doses). And the FDA’s removal of semaglutide from the shortage list on Feb 21 2025 narrowed — but did not eliminate — the legal lane for 503A compounding.

If you have no insurance, no government coverage, and you need a GLP-1 in 2026, the decision tree is short:

[provider=”ro”]

Path 1: LillyDirect Zepbound Vials ($299-$449/mo)

LillyDirect is Eli Lilly’s direct-to-patient pharmacy. On Feb 23 2026, Lilly cut the cash-pay price on its single-dose Zepbound vials — the cheapest brand-name GLP-1 path that exists in May 2026 if you want an FDA-approved finished drug without insurance.

The current price grid:

• 2.5mg vial: $299/month
• 5mg vial: $399/month
• 7.5mg, 10mg, 12.5mg, 15mg vials: $449/month — but only if you refill within 45 days of your previous fill
• 12.5mg and 15mg outside the 45-day window: jump back to $849 and $1,049 respectively

The 45-day refill rule is the silent gotcha. Miss it once on the 12.5mg or 15mg dose and your monthly cost doubles. Auto-refill via the LillyDirect portal is the most reliable workaround.

Mounjaro (tirzepatide for type 2 diabetes) uses the same vial pricing as Zepbound at LillyDirect. If your prescriber writes for Mounjaro instead of Zepbound, the cash math is identical — but only Mounjaro is on-label for T2D and only Zepbound is on-label for obesity, so prescribers will route based on diagnosis.

Path 2: NovoCare Wegovy Self-Pay ($149-$349/mo)

NovoCare is Novo Nordisk’s direct self-pay portal — the equivalent of LillyDirect for Wegovy and Ozempic. Novo restructured its pricing on Nov 17 2025 with an aggressive introductory window that runs through Jun 30 2026 for some doses.

NovoCare Wegovy pricing matrix (May 2026):

The intro prices apply only to your first two fills. Plan for $349/mo as your steady-state Wegovy cost if you stick with brand. Also note: NovoCare self-pay is not available to Medicare or Medicaid beneficiaries — even if you pay cash and bypass your government coverage, the manufacturer’s program is restricted to commercial-cash patients only. The new Medicare GLP-1 Bridge program launches Jul 1 2026 for Wegovy and Zepbound KwikPen (vials excluded).

Path 3: Compounded Semaglutide / Tirzepatide via 503A Telehealth ($99-$397/mo)

This is the cheapest path — and the most regulatorily ambiguous. Since the FDA removed semaglutide from its drug shortage list on Feb 21 2025 (tirzepatide had already been resolved earlier), mass 503B compounding from the bulks list ended in May 2025. What remains legal in 2026 is 503A patient-specific compounding: a pharmacy can compound a GLP-1 for an individual patient under that patient’s prescription, but cannot mass-produce or stockpile.

The April 30 2026 FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List has a public comment window open through Jun 29 2026. If finalized, this would further restrict the compounding ecosystem. Read our compounded vs branded semaglutide guide for the full regulatory breakdown.

Three telehealth providers dominate the compounded GLP-1 market in May 2026:

[provider=”mochi-health”]

Mochi Health: $79/mo membership (first month $39) plus $99/mo compounded semaglutide — total ~$178/mo. Compounded tirzepatide is $199/mo plus membership (~$278/mo total). Mochi advertises a 10% average loss in 6 months and 36 lb average loss in year 1. Risk flags: ~1,296 BBB complaints and a Washington State action against its affiliated Aequita pharmacy. See our Mochi Health review for the full provider profile.

[provider=”remedy-meds”]

Remedy Meds: Compounded semaglutide $189-$299/mo by dose, bundled with provider visits and shipping. Some plans accommodate brand-name Wegovy or Zepbound through insurance routing. See our Remedy Meds review.

Henry Meds: Compounded semaglutide $197-$397/mo by dose (oral $99-$149/mo); compounded tirzepatide starts at $199/mo. Advertised “starting at $179” applies to liraglutide or 12-month prepay. Trustpilot 4.5/5 across ~12,000 reviews — but Trustpilot itself flagged the profile for suspected inauthentic reviews. BBB rates Henry an F for 100% non-response to 25 complaints. Eli Lilly sued Henry Meds in April 2025 over compounded tirzepatide marketing; litigation ongoing.

Trim Rx: A newer fourth option with flat published pricing — compounded oral semaglutide $179/mo, injectable semaglutide $199/mo, and compounded tirzepatide $349/mo flat at every dose, with no separate membership fee (as of June 2026). LegitScript-certified but young (founded 2024), with a Trustpilot rating of 3.2/5; see our Trim Rx review for the complaint patterns and billing terms.

The compounded tradeoff in plain English: you save $100-$250/mo versus brand. You’re getting a drug that the FDA has not approved as a finished product. The compounding pharmacy is regulated, but the finished compounded vial is not subject to the same QC, labeling, or post-market surveillance as a Wegovy or Zepbound pen.

Path 4: HSA/FSA Tax-Stacking (22-37% Effective Discount)

An HSA (Health Savings Account) or FSA (Flexible Spending Account) lets you pay for qualified medical expenses with pre-tax dollars. GLP-1s prescribed for obesity or T2D qualify as long as you have a prescription on file.

2026 contribution limits:

• HSA (self-only): $4,300
• HSA (family): $8,550
• HSA catch-up (55+): +$1,000
• FSA (health): $3,300

The effective discount math: If you’re in the 22% federal bracket plus 7.65% FICA (employee HSA contributions skip FICA too, unlike FSA), your effective tax savings are about 29.65%. In the 24% bracket: 31.65%. In the 32% bracket: 39.65%. State income tax stacks on top in most states (HSA contributions are state-tax-free in all states except California and New Jersey).

So a $299/mo LillyDirect Zepbound vial paid through an HSA in a 24% federal bracket effectively costs ~$204/mo. Over a full year, you save ~$1,135 on $3,588 of spend.

Do you need a Letter of Medical Necessity? For most HSA/FSA debit-card purchases at a pharmacy, no — the prescription is sufficient. Some plan administrators ask for one if you’re submitting a manual reimbursement claim. Your prescriber can write one in 5 minutes; it should reference your BMI, comorbidities, and the FDA-approved indication.

Annual Cost Math: Which Path Wins Over 12 Months?

Brand-name floor: $3,588/year on LillyDirect Zepbound 2.5mg — but most patients escalate to 5mg or higher within 4-6 months, bringing the realistic annual cost to $4,500-$5,200.

Wegovy NovoCare blended: assume 2 months at $199 intro + 10 months at $349 = $3,888/year.

Mochi Health compounded semaglutide flat rate: $2,136/year ($178/mo × 12).

Stacking HSA on top of the cheapest brand path (LillyDirect Zepbound 2.5mg) in a 24% bracket: effective ~$2,450/year. That’s within $300 of the Mochi compounded cost and you’re on an FDA-approved drug.

For a fuller cost breakdown by drug and insurance status, see our Wegovy vs Zepbound cost comparison and the Zepbound product page.

GoodRx and Retail Pharmacy: Where the Markup Lives

GoodRx coupons rarely beat NovoCare or LillyDirect on Wegovy, Ozempic, or Zepbound in 2026. Retail cash prices at CVS, Walgreens, and Walmart for brand Ozempic run $800-$1,100/mo; GoodRx typically shaves this to $850-$950. The manufacturer self-pay programs ($199-$349 at NovoCare, $299-$449 at LillyDirect) are dramatically cheaper.

Where GoodRx still helps: generic comorbidity meds (metformin, statins, BP meds) that prescribers commonly co-prescribe with GLP-1s.

What to Avoid: Pharmacy Markups and Dose-Escalation Fees

Three traps catch cash-pay patients:

1. Local compounding pharmacies charging $400+/mo for the same product Mochi or Remedy bundle at $178-$299. Telehealth providers buy compounded GLP-1s at volume; standalone local compounders mark up aggressively.
2. Telehealth providers that hike pricing when you escalate dose. Mochi’s flat $99/mo compounded semaglutide doesn’t change with dose; Henry’s pricing does ($197 at low dose, $397 at higher doses). Read the dose-pricing matrix before committing.
3. “Starting at” pricing that requires 12-month prepay. Henry’s “starting at $179” is liraglutide (an older, less effective GLP-1) or a 12-month prepayment. The realistic semaglutide entry price is $197/mo.

When ‘Cheapest’ Becomes ‘Risky’

The honest line between cheap and risky in GLP-1 cash pay is the pharmacy oversight question. LillyDirect and NovoCare ship FDA-approved finished drugs manufactured under Novo or Lilly’s QC. 503A compounded GLP-1s are dispensed by state-licensed pharmacies but the finished vial is not FDA-approved.

In May 2026 the regulatory direction is clearly tightening: semaglutide off the shortage list, the April 30 2026 503B Bulks List proposal, the ongoing Eli Lilly v. Henry Meds case. If you choose a compounded path, choose a telehealth provider that names its 503A pharmacy and can show state licensure. Avoid providers that won’t disclose pharmacy partner identity.

For a side-by-side of all the cash-pay telehealth options, see our best GLP-1 telehealth 2026 guide. For a national overview, visit our weight-loss provider comparison hub.

Frequently Asked Questions

Sources

• LillyDirect Zepbound self-pay pricing (verified May 2026)
• LillyDirect Self-Pay Journey Program terms (verified May 2026)
• NovoCare Wegovy savings offer (verified May 2026)
• FDA — Policies for Compounders as GLP-1 Supply Stabilizes
• IRS Publication 969 — HSAs and Other Tax-Favored Health Plans
• BBB profile — Mochi Health (1,296 complaints noted)

Medical disclaimer: Information here is educational only. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.